Navigation Links
Burcon announces GRAS status for Puratein(R) & Supertein(TM)

VANCOUVER, Oct. 7 /PRNewswire-FirstCall/ - Burcon NutraScience Corporation (TSX-V: BU) announced today that its Puratein(R) and Supertein(TM) canola protein isolates are GRAS (Generally Recognized As Safe) for their intended use in a variety of food and beverage applications. The products have been self-affirmed GRAS through an independent evaluation by a panel of qualified experts in the fields of food safety, toxicology, nutritional sciences, food allergies and pediatric nutrition. Burcon's Puratein(R) and Supertein(TM) are the first canola protein isolates to have attained GRAS status in the United States. GRAS status permits Puratein(R) and Supertein(TM) to be marketed and used in a variety of mainstream foods and beverages for human consumption.

Puratein(R) and Supertein(TM) are expected to participate with soy, dairy and egg proteins in the multi-billion dollar global protein ingredient market. Protein ingredients are valued for both their nutritional qualities as well as their functional applications in foods and beverages.

Puratein(R) is a canola protein isolate with functional properties that include emulsification, gel formation, thickening, formation of heat-stable foams, and water- and ingredient-binding. Applications for Puratein(R) include dressings, meat substitutes, baked goods and protein bars, among many others.

Supertein(TM) is a canola protein isolate with functional properties including excellent solubility, the ability to form transparent solutions and foaming. Applications for Supertein(TM) include beverages, confectionery, aerated desserts, and protein bars, among many others. Nutritionally, the proteins are equally exciting with unique amino acid profiles.

"Achieving GRAS status is a major advancement in the commercialization of Puratein(R) and Supertein(TM), the world's first food-grade canola proteins," stated Johann F. Tergesen, Burcon's President & COO who added, "We benefited from the expertise of our

SOURCE Burcon NutraScience Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
2. Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection
3. Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
4. Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics
5. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
6. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
7. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
8. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
9. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
10. Evalve Announces Enrollment Completion of the EVEREST Randomized Study
11. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
Post Your Comments:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):